Rapport Therapeutics launches $200 million stock and $150 million convertible notes offerings
Rapport Therapeutics announced separate underwritten public offerings of $200 million of common stock and $150 million of convertible senior notes due 2032. The offerings include a 30‑day over‑allotment option for an additional $30 million of stock and $22.5 million of notes. Proceeds are earmarked for clinical trials of its lead drug RAP‑219, other R&D, working capital and possible future acquisitions. The offerings are managed by Morgan Stanley, Leerink Partners and Evercore ISI and are subject to market conditions.
Why it matters
The capital raise will provide funding for Rapport’s upcoming clinical trials and other research activities, potentially extending its cash runway. Investors should note that the offerings are not guaranteed to close and may be diluted if the over‑allotment options are exercised.
Key facts
- 1Rapport launched a $200 million common stock offering. stocktitan.net
- 2Rapport launched a $150 million convertible senior notes offering due December 1 2032. stocktitan.net
- 3The underwriters have a 30‑day option to purchase an additional $30 million of common stock. investing.com
- 4The underwriters have a 30‑day option to purchase an additional $22.5 million of notes. investing.com
- 5The notes may be redeemed for cash starting December 6 2030 if the stock price reaches at least 130 % of the conversion price. investing.com
- 6Morgan Stanley, Leerink Partners and Evercore ISI are joint book‑running managers for both offerings. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.